No profile data available.
Passage Bio, Inc. (PASG) is a healthcare company in the brain and nerve treatment drugs industry, based in Philadelphia, United States, with about 24 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$64.77 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $11.87 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Passage Bio reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$11.87 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Athira Pharma, Inc. (ATHA), Aeon Biopharma, Inc. (AEON), BioVie Inc. (BIVI), Brainstorm Cell Therapeutics Inc. (BCLI).